CagriSema post hoc analysis reports 25% weight loss in women across menopause stages
The REDEFINE 1 subgroup look, presented at The Menopause Society meeting, has not been peer reviewed and assigned menopause status retrospectively.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 22 17:30 ETSource: NewBeauty
The wire
- 01Among more than 2,300 women with overweight or obesity in the 68-week REDEFINE 1 trial, estimated average weight loss on CagriSema was 25%, versus 19% for semaglutide, 13% for cagrilintide and 3% for placebo.
- 02Estimated loss was about 27% premenopausal, 25% perimenopausal and 23% postmenopausal, with waist reductions, but the analysis does not show the drug addresses menopausal hormonal change.
- 03About 80% on CagriSema reported digestive side effects versus 40% on placebo, nausea 55%, and roughly 6% discontinued; the Novo Nordisk-sponsored analysis was post hoc and unpublished.
From the source
Read at newbeauty.comCould CagriSema Help With Menopause Weight Gain?
If you’re in your late 40s or 50s and suddenly feel like nothing moves the needle on the scale, this news may catch your attention. A new analysis of a trial testing Novo Nordisk’s experimental weight-loss shot, CagriSema, found that women taking the combination lost an estimated average of 25 percent of their body weight over 68 weeks.
